Trial | NCT00028743  Report issue

Title

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    819
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIB, stage III, or stage IV ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
OBJECTIVES:

Compare the efficacy of cisplatin and topotecan followed by paclitaxel and carboplatin vs paclitaxel and carboplatin only, in terms of time to disease progression, in patients with newly diagnosed stage IIB-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Compare the overall survival of patients treated with these regimens.
Compare the clinical objective response rates in patients with measurable disease at baseline treated with these regimens.
Compare the toxic effects of these regimens in these patients.
Compare the CA 125 normalization rates in patients treated with these regimens.
Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, age (65 years and under vs over 65 years), and pre-randomization surgery (no debulking vs debulking with macroscopic residual disease less than 1 cm vs debulking with macroscopic residual disease 1 cm or greater vs debulking with no macroscopic residual disease). Patients are randomized to one of two treatment arms.

Arm I: Patients receive cisplatin IV over 60 minutes on day 1 and topotecan IV over 30 minutes on days 1-5 of courses 1-4 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of courses 5-8.
Arm II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of courses 1-8.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Planned interval debulking surgery should occur after course 3 or 4.

Quality of life is assessed at baseline; on day 1 of courses 3, 5, and 7; at the end of the last course; and at 3 and 6 months after study treatment completion.

Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 800 patients (400 per treatment arm) will be accrued for this study within 2 years.
Study Started
Aug 31
2001
Primary Completion
Mar 05
2008
Study Completion
Jan 10
2013
Last Update
Apr 02
2020

Drug carboplatin

Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle

Drug cisplatin

4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle

Drug paclitaxel

Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle

Drug topotecan hydrochloride

4 cycles .75mg/m2 (30 mins) days 1-5 of 21 day cycle

Cisplatin, Topotecan, Paclitaxel plus Carboplatin Active Comparator

Arm 1

Paclitaxel plus Carboplatin Active Comparator

Arm 2

Criteria 

DISEASE CHARACTERISTICS:

Histologically confirmed stage IIB-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer

No borderline ovarian tumors
Residual disease allowed

Fine needle aspiration showing an adenocarcinoma is allowed instead of open or true-cut biopsy if the following are true:

Presence of pelvic mass AND
Omental cake or other metastasis larger than 2 cm in the upper abdomen unless proven stage IV disease AND
Serum CA 125/carcinoembryonic antigen ratio at least 25 (if less than 25, a barium enema or colonoscopy and gastroscopy or radiological examination of the stomach should be negative for primary tumor within 6 weeks of study) AND
Normal mammography within 6 weeks of study

PATIENT CHARACTERISTICS:

Age:

18 to 75

Performance status:

ECOG 0-1

Life expectancy:

At least 12 weeks

Hematopoietic:

Granulocyte count at least 2,000/mm^3
Platelet count at least 150,000/mm^3

Hepatic:

Not specified

Renal:

Creatinine no greater than upper limit of normal

Cardiovascular:

No clinically relevant atrial or ventricular arrhythmias
No myocardial infarction (MI) within the past 6 months (pretreatment ECG as only evidence of MI allowed)
No history of second- or third-degree heart blocks unless pacemaker implanted
History of first-degree heart block allowed

Other:

Not pregnant or nursing
Fertile patients must use effective contraception
No complete bowel obstruction
No prior allergic reaction to drugs containing Cremophor EL or compounds chemically related to study drugs
No condition that would preclude high-volume saline diuresis
No significant neurologic or psychiatric disorder that would preclude study compliance
No active uncontrolled infection
No neuropathy greater than grade 1
No pre-existing hearing loss greater than grade 1
No other concurrent serious illness or medical condition that would preclude study participation
No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No concurrent biological response modifiers or immunotherapy

No concurrent prophylactic colony-stimulating factors (CSFs)

Concurrent therapeutic CSFs allowed

Chemotherapy:

No prior chemotherapy for ovarian cancer
No other concurrent cytotoxic agents

Endocrine therapy:

No concurrent anticancer hormonal therapy

Radiotherapy:

No prior radiotherapy for ovarian cancer

Surgery:

No more than 6 weeks since prior planned pre-chemotherapy surgery for ovarian cancer
Planned interval debulking allowed
Concurrent second-look surgery allowed

Other:

No prior non-surgical therapy for ovarian cancer
No other concurrent investigational drug therapy
No other concurrent anticancer treatment
Concurrent enrollment on CAN-NCIC-OV13/EORTC 55971 allowed
No Results Posted